MycRx is developing oral, small molecule inhibitors that directly target Myc, oncology's 'mega target'. A key driver of all 'Hallmarks of Cancer', >1M new cancer patients are diagnosed annually with overexpressed Myc protein. MycRx compounds display potent cellular Myc target engagement driving profound transcriptional inhibition & on-target mechanistic profiles, resulting in compelling anti-cancer activity. Ready for Late Lead Optimization, our chemistry is on a clear path to development candidate nomination, underpinned by proprietary structural biology revealing a unique, druggable site, potentially a key breakthrough in drugging Myc.
Originally based in Melbourne, Australia, MycRx closed a Series A US-led venture capital round and has restructured as a Delaware corporation, with a growing North American Management team.
Company Details
Mycrx Questions
Mycrx's website is mecrx.com
Mycrx's LinkedIn profile is https://au.linkedin.com/company/mycrx
Mycrx has
13 employees.
View email and phone details for 13
employees at Mycrx.
Mycrx's industry is
Biotechnology Research
Mycrx's top competitors are
Brandon Capital,
Amplia Therapeutics Limited,
Rage Biotech,
Grove Biopharma, Inc.,
Gertrude Biomedical,
Okogen, Inc.,
Certa Therapeutics,
Kestrel Therapeutics,
Otifex Therapeutics,
Elevation Oncology.
Mycrx's categories are Biotechnology Research
Mycrx's founding year is 2013
